197 related articles for article (PubMed ID: 11438467)
1. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.
Sánchez-Beato M; Sáez AI; Navas IC; Algara P; Sol Mateo M; Villuendas R; Camacho F; Sánchez-Aguilera A; Sánchez E; Piris MA
Am J Pathol; 2001 Jul; 159(1):205-13. PubMed ID: 11438467
[TBL] [Abstract][Full Text] [Related]
2. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Bai M; Vlachonikolis J; Agnantis NJ; Tsanou E; Dimou S; Nicolaides C; Stefanaki S; Pavlidis N; Kanavaros P
Mod Pathol; 2001 Nov; 14(11):1105-13. PubMed ID: 11706071
[TBL] [Abstract][Full Text] [Related]
3. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
[TBL] [Abstract][Full Text] [Related]
4. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
Pinyol M; Hernández L; Martínez A; Cobo F; Hernández S; Beà S; López-Guillermo A; Nayach I; Palacín A; Nadal A; Fernández PL; Montserrat E; Cardesa A; Campo E
Am J Pathol; 2000 Jun; 156(6):1987-96. PubMed ID: 10854221
[TBL] [Abstract][Full Text] [Related]
5. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma.
Child FJ; Scarisbrick JJ; Calonje E; Orchard G; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2002 Jun; 118(6):941-8. PubMed ID: 12060387
[TBL] [Abstract][Full Text] [Related]
8. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
9. Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype.
García-Sanz R; Vargas Montero M; Gonzalez Díaz M; del Carmen M; Santos C; Balanzategui Echevarria A; Flores Corral T; Hernández Martín JM; Caballero Barrigón MD; San Miguel JF
Haematologica; 1998 Mar; 83(3):209-16. PubMed ID: 9573674
[TBL] [Abstract][Full Text] [Related]
10. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Schmidt M; Fan Z
Oncogene; 2001 Sep; 20(43):6164-71. PubMed ID: 11593424
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
12. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
13. Expressions of the CIP/KIP family of CDK inhibitor proteins in primary intestinal large B-cell lymphomas: correlation with clinical outcomes.
Go JH
Pathol Res Pract; 2002; 198(11):741-6. PubMed ID: 12530577
[TBL] [Abstract][Full Text] [Related]
14. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
16. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression.
Villuendas R; Sánchez-Beato M; Martínez JC; Saez AI; Martinez-Delgado B; García JF; Mateo MS; Sanchez-Verde L; Benítez J; Martínez P; Piris MA
Am J Pathol; 1998 Sep; 153(3):887-97. PubMed ID: 9736037
[TBL] [Abstract][Full Text] [Related]
17. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
18. Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas.
Bai M; Tsanou E; Skyrlas A; Sainis I; Agnantis N; Kanavaros P
Anticancer Res; 2007; 27(4B):2345-52. PubMed ID: 17695524
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma.
Baba Y; Tsukuda M; Mochimatsu I; Furukawa S; Kagata H; Satake K; Koshika S; Nakatani Y; Hara M; Kato Y; Nagashima Y
Cancer Detect Prev; 2001; 25(5):414-9. PubMed ID: 11718447
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
